Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Incyte announced that the European Commission has granted marketing authorization for Opzelura (ruxolitinib) cream, marking it as the first approved treatment for repigmentation in non-segmental vitiligo within the European Union.
This approval is based on positive Phase 3 trial results showing substantial improvements in facial and total body repigmentation with the treatment. Approximately 29.8% and 30.9% of patients achieved a 75% improvement in facial vitiligo after 24 weeks of treatment. The cream is designated for use in adults and adolescents aged 12 and older, addressing a significant unmet need for patients suffering from this chronic autoimmune disease.
No serious treatment-related side effects were reported, although acne at the application site was noted as a common reaction.
Incyte has announced its participation in two key investor conferences in May 2023. The company will present at the Bank of America 2023 Health Care Conference on May 10, 2023, at 10:40 a.m. (PDT), and at the 2023 RBC Capital Markets Global Healthcare Conference on May 16, 2023, at 10:30 a.m. (EDT). Both presentations will be available via live webcast at Investor.Incyte.com and can be replayed for 30 days following the events. Incyte, based in Wilmington, Delaware, specializes in developing proprietary therapeutics to address serious unmet medical needs.